Research programme: kallikrein inhibitors - BridgeBio Pharma

Drug Profile

Research programme: kallikrein inhibitors - BridgeBio Pharma

Alternative Names: Kallikrein 5/7/14 inhibitor - BridgeBio Pharma

Latest Information Update: 08 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BridgeBio Pharma
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Congenital ichthyosiform erythroderma

Most Recent Events

  • 08 Feb 2018 kallikrein inhibitors is available for licensing as of 08 Feb 2018. (BridgeBio Pharma pipeline, February 2018)
  • 08 Feb 2018 Early research in Congenital ichthyosiform erythroderma in USA before February 2018 (BridgeBio Pharma pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top